Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Addressing the regulatory and scientific challenges in multiple sclerosis - a statement from the EU regulators.
Social support and depressive symptoms among caregivers of veterans with multiple sclerosis.
Myelinating Cultures: An In Vitro Tool to Identify Demyelinating and Axopathic Autoantibodies.
Spinal segmental myoclonus as an unusual presentation of multiple sclerosis.
Glatiramer acetate-induced lobular panniculitis and skin necrosis.
Multiple sclerosis influences on the augmentation of serum Klotho concentration.
[Immunoregulative effect of Fasudil on encephalomyelitic T cells in experimental autoimmune encephalomyelitis mice].
RAD001 (everolimus) attenuates experimental autoimmune neuritis by inhibiting the mTOR pathway, elevating Akt activity and polarizing M2 macrophages.
Development of a Short Version of MSQOL-54 Using Factor Analysis and Item Response Theory.
Apoptosis of Oligodendrocytes during Early Development Delays Myelination and Impairs Subsequent Responses to Demyelination.
Therapeutic Approach to the Management of Pediatric Demyelinating Disease: Multiple Sclerosis and Acute Disseminated Encephalomyelitis.
Casein kinases as potential therapeutic targets.
Tropisetron diminishes demyelination and disease severity in an animal model of multiple sclerosis.
T-bet is essential for Th1-mediated, but not Th17-mediated, CNS autoimmune disease.
Circulating dendritic cells of multiple sclerosis patients are proinflammatory and their frequency is correlated with MS-associated genetic risk factors.
Clinical Outcome of 50 Progressive Multiple Sclerosis Patients Treated with Cellular Therapy in Iraq.
Occurrence of adverse events in chronic intrathecal baclofen infusion: a one-year follow-up study of 158 adults.
White matter disease: Aquaporin-4 antibody-positive patients may not always fulfil the clinical criteria for neuromyelitis optica.
Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life.
Heterodimerization of p45-p75 Modulates p75 Signaling: Structural Basis and Mechanism of Action.
Web search behavior and information needs of people with multiple sclerosis: focus group study and analysis of online postings.
The EIIIA domain from astrocyte-derived fibronectin mediates proliferation of oligodendrocyte progenitor cells following CNS demyelination.
MR venography in patients with multiple sclerosis and correlation with clinical and MRI parameters.
Isoniazid in autoimmunity: a trigger for multiple sclerosis?
Consistent reduction in the annualized rate of brain volume loss across phase 3 core and extension trials of fingolimod in relapsing multiple sclerosis.
Pages
« first
‹ previous
…
635
636
637
638
639
640
641
642
643
…
next ›
last »